BIOR News and Press, Biora Therapeutics Inc. From 12/30/22

SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will effect a reverse stock split of all outstanding shares of the company’s common stock at a ratio of 25 to 1. The c...

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced acceptance of two abstracts presenting patient data on its targeted therapeutics delivery system for presentation at the Crohn&#...

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed an agreement to license its Preecludia™ rule-out test for preeclampsia to Avero Diagnostics, forme...

Biora Therapeutics press release ( NASDAQ: BIOR ): Q3 GAAP EPS of -$0.03 beats by $0.04 . Revenue of $0.08M (-55.6% Y/Y) misses by $0.02M . For further details see: Biora Therapeutics GAAP EPS of -$0.03 beats by $0.04, revenue of $0.08M misses by $0.02M ...

Biora Therapeutics, Inc. (BIOR) Q3 2022 Results Conference Call November 14, 2022 04:30 PM ET Company Participants Alexandra Schuman - IR, LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Parti...

Presented results of human study at the American College of Gastroenterology annual meeting, demonstrating promising device performance in active ulcerative colitis patients Executed a registered direct capital raise of $9.75 million Presented preclinical results demonst...

Biora Therapeutics ( NASDAQ: BIOR ) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$0.07 (+81.6% Y/Y) and the consensus Revenue Estimate is $0.1M (-44.4% Y/Y). Over the last 3 months, EPS estima...

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report third quarter ended September 30, 2022 financial results on Monday, November 14, 2022 after the close ...

Biora Therapeutics ( NASDAQ: BIOR ) shares plunged 17% Monday morning after the biotech company announced a $9.75M securities offering. The firm entered into a definitive agreement with institutional investors for the purchase and sale of 32,506,250 shares of its common ...

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale, in a registered di...